Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.44 |
| ▸ | HTR3B | O95264 | 1/20 | 0.44 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.44 |
| ▸ | HTR3A | P46098 | 1/20 | 0.44 |
| ▸ | HTR3D | Q70Z44 | 1/20 | 0.44 |
| ▸ | HTR3C | Q8WXA8 | 1/20 | 0.44 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.43 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.43 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.43 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27057377 | 0.88 | GAA (0.42) | HTR3EHTR3BCHRNA7HTR3AHTR3D | |
| SCHEMBL27059669 | 0.82 | GAA (0.38) | HTR3EHTR3BCHRNA7HTR3AHTR3D | |
| SCHEMBL27057660 | 0.80 | GAA (0.47) | HTR3EHTR3BCHRNA7HTR3AHTR3D | |
| SCHEMBL27107054 | 0.79 | GAA (0.40) | HTR3EHTR3BCHRNA7HTR3AHTR3D | |
| SCHEMBL27052345 | 0.79 | GAA (0.48) | HTR3EHTR3BCHRNA7HTR3AHTR3D | |
| SCHEMBL24278797 | 0.79 | CHRM2 (0.46) | HTR3EHTR3BCHRNA7HTR3AHTR3D | |
| SCHEMBL27057357 | 0.79 | GAA (0.50) | HTR3EHTR3BCHRNA7HTR3AHTR3D | |
| SCHEMBL25755384 | 0.79 | CHRM2 (0.46) | HTR3EHTR3BCHRNA7HTR3AHTR3D | |
| SCHEMBL27058566 | 0.78 | GAA (0.42) | HTR3EHTR3BCHRNA7HTR3AHTR3D | |
| SCHEMBL27106974 | 0.77 | GAA (0.41) | HTR3EHTR3BCHRNA7HTR3AHTR3D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240067763-A1 | SOLID TITANIUM CATALYST COMPONENT, OLEFIN POLYMERIZATION CATALYST, OLEFIN POLYMERIZATION METHOD, AND PROPYLENE POLYMER | MITSUI CHEMICALS, INC. (JP) | 2024-02-29 | — | — | US | disclosed |
| US-20240025838-A1 | ESTER COMPOUND | MITSUI CHEMICALS, INC. (JP) | 2024-01-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240025838-A1 | ESTER COMPOUND | NR1H3, CYP4A11, H1-4 | HTR3E 1981/4885HTR3B 1882/4885CHRNA7 3219/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.